Hemothorax under thrombolytic therapy with recombinant tissue: plasminogen activator (rt-PA) in a 16-year-old girl.
We present the case of a 16-year-old girl with an extended thrombosis of the femoral and iliac vein and the inferior vena cava during pleuropneumonia; predisposing risk factors for thrombophilia were: use of contraceptives, nicotine abuse and congenital deficiency of antithrombin III (not previously diagnosed). Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA; initial dose: 0.08 mg/kg/h) was started. 2 days later--after diagnosis of an extended hemothorax: 1500 ml blood were obtained after thoracocentesis, transfusion of packed red blood cells was necessary--rt-PA was stopped, with only heparin (400 U/kg/d) being administered. 36 h later--the thrombosis had not yet changed--the thrombolytic therapy with rt-PA was continued in a markedly reduced dose (0.015 mg/kg/d) with no further bleeding complications. 8 days later--after successful thrombolysis--t-PA was stopped, heparin was given for another 10 days, then cumarin was administered orally.
Varnholt
V
V
Department of Pediatrics, Universitäts-Klinikum Charité, Berlin, Germany. verena.varnholt@charite.de
Ringe
H
H
Nietsch
L
L
Gaedicke
G
G
D000293:Adolescent; D005260:Female; D006491:Hemothorax / Q000139:chemically induced*; D006801:Humans; D011001:Pleuropneumonia / Q000150:complications; D011994:Recombinant Proteins; D015912:Thrombolytic Therapy / Q000009:adverse effects*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects*; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy
D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator